Pharmaceutically acceptable salt and solvate of triazolopyridinylsulfanyl compound as p38 map kinase inhibitor

Abstract

This invention relates to a pharmaceutically acceptable salt and / or solvate (including hydrate) of a compound of formula (I): and its use in the treatment of a TNF mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.